Enhancing Trial Design for Atypical AD

Abstract

This session will propose key considerations for advancing clinical trials targeting atypical Alzheimer’s disease (AD) variants. AD variants include early‐onset disease as well as atypical clinical presentations such as prominent language or visuospatial dysfunction. For therapeutic trials, variants may be evaluated singly or combined.

The paper